Clinical Trials Logo
  1. Home
  2. Other
  3. NCT06461182

Ga-68-CXCR4 PET/CT in Indolent B-cell Lymphoma — PentixaFor  

Indolent B-Cell Non-Hodgkin Lymphoma Clinical Trial

Official title:
Ga-68-CXCR4 PET/CT in Detecting, Evaluating Response to Treatment, and Monitoring Risk of Aggressiveness of Indolent B-cell Lymphoma

Clinical Trial Summary

This study explores the efficacy of Ga-68-PentixaFor PET/CT in detecting, assessing treatment response, and monitoring the risk of aggressiveness in indolent B-cell lymphoma. The background introduces CXCR4 and discusses its role in cancer research. Currently, FDG-PET is the primary imaging tool for lymphoma staging, but it lacks diagnostic accuracy for low-grade lymphomas. Ga-68-PentixaFor PET demonstrates promising detection capabilities across various lymphomas, suggesting its potential as a superior imaging modality for low-grade lymphomas.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06461182
Study type Interventional
Source Koo Foundation Sun Yat-Sen Cancer Center
Contact Yu Yi Huang, MD
Phone +886 28970011
Email yuyi@kfsyscc.org
Status Recruiting
Phase Phase 2
Start date April 29, 2024
Completion date April 2027
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05803395 - Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy.
Active, not recruiting NCT04578600 - CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma Phase 1
Recruiting NCT05025800 - ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma Phase 1/Phase 2
Recruiting NCT03571568 - A Study of BI-1206 in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma Phase 1/Phase 2
Recruiting NCT06386315 - Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma Phase 2
Recruiting NCT05169658 - Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma Phase 2
Recruiting NCT05621096 - Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma Phase 1
Recruiting NCT05665062 - Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies Phase 1
Active, not recruiting NCT03498612 - Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases Phase 2